KLK3 and metastatic neoplasm: Some clinical details have been obfuscated for privacy purposes. Our patient was a gentleman in his 60s who presented with a chief complaint of a rising prostate-specific antigen (PSA) approximately 10 years after low dose rate (LDR) brachytherapy for prostate cancer. Originally, he had presented in his 50s with a Gleason 3+4 (Grade group 2) prostate cancer, with pre-treatment PSA <10, and non-palpable (T1c) disease. At the time of initial prostate cancer presentation, staging scans (CT of the abdomen and pelvis and nuclear medicine bone scan) were negative for metastatic disease.